Muco Rhinathiol Adultes (Carbocisteine)

Carbocisteine acts as a mucolytic in diseases characterised by thick respiratory secretions.

• Chronic bronchitis: thins mucus to facilitate expectoration and improve airway clearance.
• Chronic obstructive pulmonary disease (COPD): helps reduce sputum viscosity, aiding cough effectiveness.
• Productive cough associated with respiratory tract infections: promotes easier clearance of mucus, relieving cough discomfort.

• Carbocisteine cleaves disulfide bonds within mucoproteins, decreasing the viscoelastic properties of mucus. By lowering sputum viscosity, it enhances ciliary transport and expectoration, thereby improving airway patency and reducing cough reflex sensitivity.

Carbocisteine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Vomiting: occasional episodes after ingestion.
• Diarrhea: loose stools in some patients.
• Abdominal pain: discomfort or cramps.
• Headache: transient mild headache.
• Rash: mild skin irritation.

Serious or Rare Side Effects

• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes.
• Neutropenia: reduced white blood cell count.
• Bronchospasm: paradoxical airway constriction.
• Hematologic abnormalities: rare blood dyscrasias.

When using carbocisteine, consider the following safety measures.

• Renal impairment: assess kidney function before initiating therapy.
• Hepatic disease: use with caution in patients with liver disorders.
• Pregnancy: safety not established; weigh benefits against potential risks.
• Breastfeeding: unknown excretion in milk; consider alternatives.
• Concomitant medications: review for possible interactions with other mucolytics or cough suppressants.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Carbocisteine may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid)

• Antitussives containing codeine: may counteract mucolytic benefit.
• Anticholinergic agents: can reduce mucus clearance effectiveness.
• Strong bronchodilators (e.g., beta‑agonists) used simultaneously: may increase risk of bronchospasm.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of anticoagulant effect.
• Diuretics: monitor electrolyte balance.
• Other mucolytics: additive effect may increase gastrointestinal irritation.
• Antibiotics (e.g., aminoglycosides): watch for enhanced nephrotoxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): observe for gastrointestinal upset.